The prodigiosin can inhibit Wnt/β-catenin signaling and exerts anticancer activity in breast cancer cell [20] and can reactivate p53 family-dependent transcriptional activity in p53-deficient human colon cancer cells [21]. This evidence concerns the gene TP53 and breast carcinoma.